Keynote Speakers:

• Jason Coloma, Head of Oncology and Cancer Immunology Partnering, Roche
• Susan Herbert, Executive Vice-President, Global Business Development and Strategy, Merck Serono
• Vivek Ramaswamy, CEO, Axovant Sciences

Speakers & Chairs:

• Adam Kostyál, Senior Vice President GCCG, Nasdaq Stockholm AB
• Alain Huriez, Venture Partner, Advent Life Sciences
• Anish Bhatnagar, President and CEO, CAPNIA, Inc.
• Anne Portwich, Partner, Life Science Partners
• Antonius Schuh, CEO, Trovagene, Inc.
• Arthur Franken, Partner, Gilde Healthcare Partners
• Austin Smith, Medical Director, Theradex Europe Ltd.
• B. Chandler May, President & Chief Executive Officer, Inflammatory Response Research, Inc.
• Barbara Domayne-Hayman, CBO, Autifony Therapeutics Ltd.
• Barry Ticho MD, Head, Cardiovascular and Metabolic Disorders, External R&D Innovation (ERDI), Worldwide Research & Development, Pfizer, Inc.
• Bernard Bihain, CEO, Genclis SAS
• Bernard Huber, Chief Executive Officer and Founder, Oryx Translational Medicine
• Bernd Goergen, Investment Director, High-Tech Gruenderfonds Management GmbH
• Bernhard Sixt, CEO, ImmunID
• Beth Jacobs, Managing Partner, Excellentia Global Partners
• Bill Blair, Head of Business Creation, Edinburgh BioQuarter
• Bill Mullen, CEO, Momentum Bioscience Ltd.
• Bob Pooler, Sr. Healthcare Analyst, valuationLAB AG
• Carina Schmidt, CEO, Athera Biotechnologies AB
• Carlos Buesa, CEO, Oryzon Genomics
• Carole Nuechterlein, Head of Roche Venture Fund Basel, Roche Venture Fund
• Celia Zinger, Director Medical Affairs, Immune Pharmaceuticals, Inc.
• Chandra Leo, Partner, HBM Partners AG
• Charlie Alexander, Lead - BD Transactions, Shire Pharmaceutical
• Chris Britten, Managing Director, Torreya Partners (Europe) LLP
• Chris Maggos, Managing Director, Europe, LifeSci Advisors
• Chris Marai, Executive Director, Oppenheimer & Co.
• Chris Moriarty, Global Manager, Pharma Sciences Division, Randox Laboratories Ltd.
• Christian Glennie, Head of Research, Healthcare, Edison Investment Research
• Christian Lach, Portfolio Manager, Analyst, Bellevue Asset Management AG
• Christoph Pittius, VP, Head of Transactions, BD, AstraZeneca AB
• Clive Stanway, CSO, Cancer Research Technology Ltd.
• Crist Frangakis, CEO and President, Achelios Therapeutics, Inc.
• Daniel Anizon, Financial Analyst, Independent Consultant
• David Colpman, Director, Colpman Consulting Ltd.
• David Horn Solomon, President & CEO, Bionor Pharma A/S
• David Phillips, Partner, S.R. One Ltd.
• David Stueber, Managing Director Depositary Receipts, Head of Western Europe, BNY Mellon
• Deborah Harland, Partner, S.R. One Ltd.
• Deborah Van Riet, Director, Future Therapeutics & Technologies, Integrated Science & Technology, AbbVie
• Detlev Mennerich, Investment Manager, Boehringer Ingelheim Venture Fund
• Donnie McGrath, Vice President, Search and Evaluation, Business Development, Bristol-Myers Squibb
• Prof. Dorothee Holm-von Laer, Co-founder and CEO, ViraTherapeutics GmbH
• Eckhard Leifke, VP External Opportunities CV & Metabolism, Sanofi
• Eduardo Margallo, CEO, MedLumics S.L.
• Edwin Constable, Head of Research,  Professor of Chemistry at the University of Basel and Project leader and Member of the Management Board within the SNI
• Erik Buntinx, Founding CEO, PNBDevCo
• Esteban Pombo-Villar, COO, Oxford BioTherapeutics AG
• Eugene Seymour, CEO, NanoViricides, Inc.
• Fabrizio Gasparini, Director, Novartis Institutes for BioMedical Research
• Fintan Walton, CEO and Founder, PharmaVentures
• Florian Schödel, Owner, Phillimmune, LLC
• François Thomas, Managing Director, Thomas Conseil SPRL
• Frank Grams, VP, Head of R&D Alliance Management & Contracting, Sanofi
• Frederic Desdouits, Head of Corporate BD & Acquisitions, Pierre Fabre
• Gaudenz von Capeller, CFO, PIQUR Therapeutics AG
• Geert Cauwenbergh, President and CEO, RXi Pharmaceuticals Corporation
• Genghis Lloyd-Harris, Partner, Abingworth LLP
• Hakan Goker, Senior Investments Director, MS Ventures
• Harold Van Wart, President and Chief Executive Officer, Director, CymaBay Therapeutics
• Hendrik Liebers, CFO, Probiodrug AG
• Iain Dukes, SVP Business Development & Licensing, Merck Research Laboratories
• James Sapirstein, CEO, ContraVir Pharmaceuticals, Inc.
• Jana Watson-Capps, Associate Director and Head of Strategy, University of Colorado BioFrontiers Institute
• Jane Atkins, Director S&E, Center for External Innovation, Takeda Pharmaceuticals International GmbH
• Jeff Baxter, Chief Executive Officer, VBI Vaccines
• Jim Phillips, CEO, Midatech Pharma PLC
• Jim Steel, Head of Healthcare and Life Sciences, Corporate Finance, Peel Hunt LLP
• João Miguel Santos Pereira, CEO, Magnomics
• Joël Crouzet, CEO & CSO, InnaVirVax
• Johannes Zanzinger, Global Head, BD & Licensing Cardiometabolic Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG
• Joshua Resnick, Head of Merck Research Laboratories Ventures, Merck
• Jutta Roth, Business Development Manager, University of Oxford
• Katherine Cohen, CEO, Hookipa Biotech AG
• Katya Smirnyagina, Partner, Capricorn Venture Partners
• Kia Motesharei, Head, Immunology Licensing, EMD Serono
• Klaus D. Mendla, Global Head, BD & Licensing CNS, Boehringer Ingelheim Pharma GmbH & Co. KG
• Lars Gredsted, Senior Business Analyst, Wellcome Trust
• Laura Lane, Business Development Manager, Warwick Ventures Ltd.
• Laurent Choppe, Managing Partner, Cukierman & Co. Life Sciences
• Laurenz Kellenberger, Chief Scientific Officer, Basilea
• Lisa M. Rhoads, Managing Director, Easton Capital
• Loic Vincent, Head, Oncology External Innovation, Sanofi
• Lorenza Castellon, Business Development Consultant, Suda Ltd.
• Lubor Gaal, Head of Licensing and External Innovation, Almirall, S.A.
• Maarit Merla, Head of Business Development, Forendo Pharma Ltd.
• Malcolm Weir, Co-Founder and CEO, Heptares Therapeutics
• Marc Martinell, CEO, Mynoryx Therapeutics S.L.
• Maria Flocco, Senior Director, Head Strategic Research Partnerships Europe, Pfizer
• Maria Hassard, Deputy Director of Research & Development, Moorfields Biomedical Research Centre
• Margarita Chavez, Director, Ventures Investments, AbbVie, Inc.
• Mark J. Pykett, CEO, Agilis Biotherapeutics
• Markus Goebel, Partner, Novartis Venture Fund
• Markus Hosang, General Partner, BioMedPartners AG
• Martin McGlynn, President & Chief Executive Officer, StemCells, Inc.
• Masa Yuhara, General Manager, Business Development, Mitsubishi Tanabe Pharma Europe Ltd.
• Matthew Durdy, CBO, Cell Therapy Catapult
• Melya Hughes Crameri, Head of Business Development, Europe, Amunix Operating, Inc.  
• Michael Scherz, Founder & CEO, Metys Pharmaceuticals AG
• Miro Venturi, Global Head, Diagnostics Biomarkers, F.Hoffmann-La Roche Ltd
• Nanna Lüneborg, Investment Director, Novo Seeds, Novo A/S
• Nathalie ter Wengel, Director of Business Development, Galapagos
• Naveed Siddiqi, Partner, Edmond de Rothschild Investment Partners
• Nicholas Benedict, Co-Founder & CEO, Allecra Therapeutics
• Nicholas Franco, EVP  & Chief Business Development Officer, Actelion Pharmaceuticals Ltd.
• Nicola Thompson, Head, Office of External Drug Discovery, F. Hoffmann La Roche AG
• Nooman Haque, Director of Life Sciences, Silicon Valley Bank
• Oliver Middendorp, Co-CEO and CBO, Numab AG
• Oliver Siegal, CEO, AFFiRiS AG
• Ora Dar, Head of Life Sciences Sector, Office of the Chief Scientist, Ministry of Economy, Israel
• Patrick Doyle, President, KineMed, Inc.
• Paul Lammers, President and CEO, Mirna Therapeutics, Inc.
• Paul Rennert, Founder & Principal, SugarCone Biotech LLC
• Pascale Augé, CEO, Inserm Transfert
• Pedro Lichtinger, CEO, Asterias Biotherapeutics
• Peter Hoang, Senior Vice President, Business Development & Strategy, Bellicum Pharmaceuticals, Inc.
• Peter Homberg, Partner/Lawyer, Dentons Europe LLC
• Peter Nolan, CBO, Oxford Biomedica Ltd.
• Peter Sandor, Vice President, Global Marketing Oncology TA, Amgen, Inc.
• Peter Zerhouni, Chief Executive Officer, InDex Pharmaceuticals AB
• Philippe Calais, CEO, Isarna Therapeutics GmbH
• Philippe Lopes-Fernandes, Senior Vice-President, Head of Global Licensing & Business Development, EMD Serono, Inc.
• Punit Dhillon, Co-Founder, President & CEO, OncoSec Medical, Inc.
• Rahul Ballal, Director, Business Development, Flexion Therapeutics
• Rainer Metzger, VP, Global Business Development Pharma, QIAGEN GmbH
• Rainer Strohmenger, General Partner, Wellington Partners
• Rao Movva, Distinguished Scientist, Novartis Institutes for BioMedical Research
• Ronald Kempers, President & CEO, Mymetics Corporation
• Rudi Pauwels, CEO, Biocartis NV
• Saad Gilani, Managing Director & Head of Healthcare Investments, Yorkville Advisors LLC
• Seth Lederman, CEO, Tonix Pharmaceuticals Holding Corp.
• Shane Maloney, Business Development Director, AstraZeneca
• Simon Blake, Sr. Director Scientific Licensing, Janssen Pharmaceuticals
• Søren Møller, Managing Investment Director, Novo Seeds, Novo A/S
• Sten Verland, Partner, Sunstone Capital A/S
• Stéphane Boissel, Chief Executive Officer, TxCell
• Stephanie Leouzon, Principal and Head of Torreya Partners Europe, Torreya Partners (Europe) LLC
• Stephen Brozak, Managing Partner and President, WBB Securities, LLC
• Stephen Helliwell, Senior Investigator, Novartis Institutes for Biomedical Research
• Stephen Sands, Commercial Lead Oncology/Immunology, F.Hoffmann-La Roche AG
• Thomas Hanke, EVP Immunology & Inflammation, Evotec International GmbH
• Thomas Landh, Director, Strategy and Innovation Sourcing, Novo Nordisk
• Thomas Meier, Chief Executive Officer, Santhera 
• Thomas Stockman, Director, European Healthcare Investment Banking, Royal Bank of Canada
• Tim Dyer, CEO, Addex Therapeutics
• Tim Herpin, Vice President, Head of Transactions (UK), Business Development, AstraZaneca
• Tim Luker, Senior Director, External Innovation, Eli Lilly & Company
• Timothy Morris, CFO, Head of BD, AcelRx Pharmaceuticals, Inc.
• Ursula Ney, CEO, Genkyotex S.A.
• Vikas Sharma, Director, Business Development, Rexahn Pharmaceuticals, Inc.
• Vivek Ramaswamy, CEO, Axovant Sciences
• Wim Jongen, CEO, Glycostem Therapeutics Corporation
• And more to be announced...